Maybe low T isn't so bad after all. A new study found that testosterone therapies doubled the heart attack risk for men over age 65 after only three months. Heart attack risk also doubled for younger men with a history of heart disease. "This is a warning that testosterone therapy shouldn't be prescribed cavalierly," says Dr. Bradley Anawalt, a testosterone researcher at University of Washington in Seattle. "Men with borderline low testosterone but without testicular or pituitary disease should be very cautious — it is not a magic potion to restore youth, and the risks are unknown."
This and other recent studies have prompted the FDA to take another look at the safety of a number of testosterone-boosting products like AndroGel which, all told, are being taken by some 5.6 million men. "The FDA has not regulated the large promotional campaign for low T which has driven the tremendous surge in testosterone prescription," says Dr. Lisa Schwartz, a professor at the Dartmouth Institute for Health Policy and Clinical Practice. "It should."
The combination of an unbranded low testosterone disease awareness campaign, massive branded advertising campaigns for testosterone drugs and inadequate warnings and studies have combined to create a situation where alarming numbers of men are having heart attacks, strokes and pulmonary embolisms as a result of taking a drug that they thought was safe.
If you or a loved one had a heart attack, stroke, pulmonary embolism or blood clot while taking AndroGel or another testosterone medication, please call our experienced AndroGel attorneys at (888) 606-5297 for a free consultation about your potential AndroGel lawsuit.